The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) market in North America mainly includes biologics manufacturing, small molecule production, and packaging. Biologics manufacturing dominates the market owing to increasing demand for affordable biopharmaceuticals and innovation in biologics. Pharmaceutical CDMOs provide enhanced flexibility, expertise, and cost efficiency compared to in-house manufacturing. The region has stringent regulatory requirements for biopharmaceuticals that has driven CDMOs services adoption.
Key Takeaways
Key players operating in the Pharmaceutical CDMO market in North America are Pfizer Inc., Teva Pharmaceutical Industries Ltd., Sanofi S.A., Sun Pharmaceutical Industries Ltd., AstraZeneca Plc, Merck & Co., Inc., Viatris + Mylan N.V, Cipla Inc., Dr ReGeneric Drugsy's Laboratories Ltd., Samsung Biologics, Abbott Laboratories, Amgen Incorporated, Baxter International Incorporated, Becton Dickinson and Company, Bristol-Myers Squibb Company, GlaxoSmithKline Plc, Roche Holding Limited.
Key players are focusing on developing innovative biologics that are partnering with CDMOs for cost-effective manufacturing to gain competitive advantage. There is significant Generic drugs Market Demand for CDMOs services from small molecule formulations, protein therapeutics, and cell & gene therapies developers. The CDMO market players are offering integrated services from early development to commercial manufacturing for biologics.
North American region dominates the global pharmaceutical CDMO market. However, emerging Asian markets are expected to offer lucrative opportunities owing to low-cost manufacturing and availability of skilled workforce. Key market players are expanding their manufacturing facilities in Asia and other regions to cater to the global demand.
Market drivers: High burden of chronic diseases, increasing R&D expenditure of pharma companies, preference for outsourcing non-core activities, rising adoption of biologics are some key factors driving growth of pharmaceutical CDMO market in North America.
Market restraints: High capital investment requirement for setting up manufacturing facilities, stringent regulations.
Segment Analysis
The Generic Drugs Market is dominated by therapeutics segment. They account for around 60% share owing to their consistent high demand from hospitals and clinics for treatment of various chronic diseases. Generics sub segment holds the major share within therapeutics owing to their affordability and ability to provide similar efficacy at lower costs compared to branded drugs. Growing focus on reducing healthcare costs is driving demand for generic drugs globally.
Global Analysis
North America represents the largest regional market and is expected to maintain dominance over the forecast period. This can be attributed to growing occurrence of chronic diseases, rising health awareness, presence of well-established healthcare infrastructure and high adoption of advanced treatment options. Asia Pacific is projected to witness the fastest growth during the forecast period owing to rising investments by key players, growing disposable income, increasing government funding for healthcare and expansion of private healthcare facilities. Moreover, growing medical tourism industry in countries such as India and China is creating new opportunities for players in the regional market.
Get This Report In Japanese
Get This Report In Korean
About Author:
Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups.
(LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)
